Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 3.81 | 6.77 | 3.95 | 19.38 | 2.31 | 11.00 | 5.13 | 9.20 | — | — | — | — | — | — | 0.11 | — | — | — | — | — | — |
| — | -38.5% | -23.1% | +110.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.96 | 1.78 | 1.24 | 2.12 | 2.40 | 5.57 | 2.72 | 3.99 | 10.37 | 77.38 | — | — | — | — | — | 1486.67 | 4274.22 | 1880.23 | 6862.03 | 768.73 | 1163.28 |
| — | -68.1% | -54.4% | -46.8% | -76.8% | -92.8% | — | — | — | — | — | — | — | — | — | +93.4% | +267.4% | -76.4% | +567.5% | -28.8% | +142.5% | |
| P/B Ratio | 1.54 | 1.58 | 1.44 | 2.69 | 2.68 | 4.02 | 3.70 | 5.89 | 8.10 | 5.40 | 4.20 | 3.08 | 2.51 | 3.67 | 3.38 | 3.21 | 2.07 | 2.59 | 3.50 | 2.76 | 2.56 |
| — | -60.8% | -60.9% | -54.2% | -66.9% | -25.7% | -12.0% | +91.3% | +221.9% | +47.1% | +24.2% | -4.1% | +21.5% | +41.8% | -3.3% | +16.2% | -19.0% | -23.8% | -22.5% | -49.3% | -50.6% | |
| P/FCF | 3.53 | 2.09 | 3.79 | 2.94 | 8.26 | 7.39 | 5.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -71.8% | -29.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.71 | 2.89 | 2.02 | 3.94 | 5.00 | 9.22 | 4.42 | 8.76 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -68.7% | -54.5% | -55.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 4.08 | 3.26 | 2.69 | 4.70 | 5.15 | 8.93 | 4.35 | 8.50 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -63.5% | -38.2% | -44.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 75.7% | 82.5% | 83.4% | 89.3% | 95.3% | 95.9% | 96.2% | 94.0% | 36.8% | — | — | — | — | — | 98.6% | 78.5% | 98.4% | 80.0% | 14.9% | 33.9% |
| — | -20.6% | -14.0% | -13.3% | -5.0% | +159.3% | — | — | — | — | — | — | — | — | — | +563.0% | +131.2% | +229.3% | +162.3% | +645.3% | +140.8% | |
| Operating Margin | 48.2% | 42.1% | 50.0% | 46.0% | 49.2% | 49.2% | 51.5% | 41.4% | -28.7% | -1898.1% | — | — | — | — | — | -28244.7% | -102126.1% | -38773.1% | -92094.8% | -13794.9% | -22487.2% |
| — | -14.4% | -3.0% | +10.9% | +271.6% | +102.6% | — | — | — | — | — | — | — | — | — | -104.7% | -354.2% | +46.0% | -1027.3% | -26.3% | -216.8% | |
| Net Margin | 52.3% | 25.5% | 30.3% | 10.9% | 104.1% | 49.9% | 52.8% | 43.1% | -24.2% | -1755.5% | — | — | — | — | — | -27637.7% | -100538.7% | -35782.4% | -92142.8% | -13814.5% | -22498.9% |
| — | -48.9% | -42.7% | -74.7% | +529.5% | +102.8% | — | — | — | — | — | — | — | — | — | -100.1% | -346.9% | +36.7% | -1026.9% | -26.4% | -217.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.6% | 5.8% | 9.2% | 3.6% | 36.5% | 11.8% | 20.7% | 18.8% | -5.3% | -27.2% | -22.6% | -19.2% | -14.7% | -21.9% | -19.4% | -14.7% | -11.6% | -12.5% | -11.5% | -11.8% | -11.7% |
| — | -51.0% | -55.7% | -80.8% | +789.5% | +143.5% | +191.7% | +197.6% | +64.1% | -24.1% | -16.4% | -30.5% | -26.9% | -75.1% | -69.0% | -25.0% | +0.9% | -112.2% | +1.0% | +23.8% | +52.9% | |
| ROA | 34.5% | 3.0% | 4.7% | 1.8% | 21.6% | 9.9% | 15.4% | 13.7% | -4.1% | -22.5% | -19.3% | -17.0% | -13.1% | -19.4% | -17.4% | -13.2% | -10.6% | -11.5% | -10.5% | -10.8% | -11.0% |
| — | -69.3% | -69.4% | -87.0% | +627.2% | +143.8% | +179.8% | +180.6% | +68.7% | -16.1% | -10.6% | -28.6% | -24.3% | -69.2% | -65.8% | -22.5% | +3.7% | -104.3% | +2.7% | +20.8% | +46.6% | |
| ROIC | 49.7% | 8.5% | 11.8% | 10.0% | 14.4% | 26.4% | 32.3% | 28.3% | -11.7% | -55.0% | -49.5% | -40.7% | -25.9% | -29.8% | -39.4% | -47.7% | -37.9% | -42.6% | -40.9% | -81.1% | -147.1% |
| — | -67.7% | -63.5% | -64.5% | +223.0% | +148.1% | +165.2% | +169.6% | +54.9% | -84.7% | -25.5% | +14.7% | +31.6% | +30.0% | +3.7% | +41.2% | +74.2% | +52.4% | +68.0% | +60.0% | +52.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.31 | 0.33 | 0.37 | 0.40 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +15864.2% | +7892.0% | +5916.2% | +4100.1% | -84.7% | -61.9% | -35.8% | +12.2% | -14.3% | -23.8% | -34.7% | -43.0% | +7.3% | -4.4% | -0.9% | +7.8% | +9.8% | +19.2% | -37.0% | -54.9% | |
| Debt / EBITDA | 0.90 | 2.73 | 1.95 | 2.14 | 2.70 | 0.02 | 0.02 | 0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +12251.1% | +8211.7% | +5311.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.11 | 2.56 | 2.98 | 2.11 | 1.94 | 7.82 | 4.21 | 3.39 | 3.96 | 4.79 | 6.65 | 6.97 | 11.61 | 7.39 | 12.15 | 9.44 | 11.79 | 12.40 | 14.55 | 12.44 | 14.01 |
| — | -67.2% | -29.4% | -37.8% | -50.9% | +63.4% | -36.7% | -51.4% | -65.9% | -35.3% | -45.2% | -26.1% | -1.5% | -40.4% | -16.5% | -24.1% | -15.8% | -51.4% | -46.6% | +7.4% | +65.8% | |
| Quick Ratio | 1.94 | 2.36 | 2.74 | 1.94 | 1.73 | 7.52 | 3.99 | 3.16 | 3.60 | 4.43 | 6.41 | 6.78 | 11.61 | 7.39 | 12.15 | 9.44 | 11.79 | 12.40 | 14.55 | 12.43 | 14.00 |
| — | -68.6% | -31.5% | -38.8% | -52.0% | +69.9% | -37.7% | -53.4% | -69.0% | -40.1% | -47.3% | -28.1% | -1.5% | -40.4% | -16.5% | -24.1% | -15.8% | -51.4% | -46.5% | +7.7% | +66.6% | |
| Interest Coverage | 54.92 | — | — | 32.06 | 56.45 | 3051.44 | 2063.95 | 1346.50 | -276.49 | -2157.56 | -1611.70 | -2249.46 | -742.11 | -1925.78 | -1203.11 | -934.39 | -779.96 | -2283.65 | -1306.96 | -1447.68 | -1591.52 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRMD stock.
CorMedix Inc.'s current P/E is 3.8x. The average P/E over the last 4 quarters is 8.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CorMedix Inc.'s current operating margin is 48.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CorMedix Inc.'s business trajectory between earnings reports.